RALEIGH, NC, April 24, 2018 (GLOBE NEWSWIRE) --
Icon Media Holdings, Inc. (OTC: ICNM), a diversified global technology company, is pleased to report that we have entered into an agreement with DMR Biologics to assist in marketing, manufacturing and distribution of homeopathic drugs and nutritional supplements. The first products to go to market will be their patented migraine headache formula.
Migraine headache is the third most common disease state in the world. According to the Migraine Research Foundation (MRF), around 38 million men, women and children in the U.S and 1 billion people around the globe are affected by migraines as of 2017. Global Data predicts the global market size for migraine drugs should grow to $8.7 billion by 2026, at a compound annual growth rate of 10.3%. The United States will dominate the market with 77% of total sales by 2026. Over the counter migraine drugs are attributed for the significant share in the global market.
Under the agreement with DMR, ICNM will provide seed funding and online business development consulting as needed. In return, ICNM will receive a share of DMR’s gross revenue for the next several years.
Commenting on the agreement, Rob Deakin, CEO of Icon, said, "We are very excited to have an opportunity to work with DMR Biologics. Russ Mitchell has a stellar reputation and success rate for developing and marketing homeopathic drugs and nutritional supplements. While we continue to focus on building the wireless infrastructure business, we found this to be a compelling opportunity to generate revenue for the company and build shareholder value. The diligence performed on DMR suggests that the patented formula far outperforms any other over the counter migraine products currently on the market."
DMR’s CEO Russ Mitchell commented, “We are very pleased and excited to partner with Icon Media Holdings to launch our new line of migraine headache products. Our clinical studies and subsequent analysis conducted by world-class headache specialists have shown our formulations to be highly effective and very safe across a broad class of patients. While there are a number of prescription and OTC treatments in the market, their efficacy and safety are limited, leaving a large segment of sufferers underserved.”
About Icon Media Holdings, Inc. (OTC: ICNM)
www.spectrumvelocity.com
Icon Media Holdings (OTC: ICNM) is a diversified global technology company that specializes in technical and infrastructure services for the wireless industry. The Company provides turnkey small cell network, distributed antenna systems (“DAS”) and Wi-Fi technical consulting, design and implementation services through its subsidiary Spectrum Velocity™. Our customer base includes the wireless industry as well as enterprise clients.
About DMR Biologics, LLC
DMR Biologics was created to produce and distribute scientifically validated homeopathic drugs and nutritional supplements. DMR believes it can develop and produce complementary and alternative therapies that can outperform traditional allopathic treatments while being much safer and more cost effective. DMR will also begin to incorporate hemp oil into a number of formulations that have already been developed. DMR will initially target alternative health professionals including chiropractors, naturopaths and homeopaths who currently dispense treatments to their patients.
Sign up for investor updates on our website and on the investor relations page.
Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.